Our objective was to assess comorbidities and their effects on outcomes in predominantly asymptomatic populations without previous heart failure treatment of the SOLVD prevention trial , compared to symptomatic heart failure patients of SOLVD treatment and to evaluate associations to the effect of enalapril .